Skip to main content
Search hero banner

Search results

Showing 681 - 700 of 768 results

Helium polariser

Helium 3 Polariser

This state-of-the-art metastable-exchange optical-pumping helium-3 polarising system enables polarisation-analysis experiments on five of our existing instruments.

Inaugural particle therapy study tour to Japan

Australian researchers and clinicians have recently returned from Japan where they investigated the use of advanced radiation therapy for cancer using heavy ions at particle therapy facilities on a study tour .

Stewart Pullen ANSTO
Senior Business Manager

Stewart started at ACNS in 2007 after completing his Bachelor’s degree where he completed his honours projects with ANSTO.

Ms Karen Wilde
NDF User Program Manager & Protein Labelling Specialist, National Deuteration Facility
Role at ANSTO

What's new in nuclear power technologies

It's ANSTO's role to keep Australia across the very latest developments in nuclear science and technology from around the world. Part of this responsibility is keeping us abreast of the latest developments in nuclear power technologies.

Chronic Kidney disease of unknown origin

Chronic kidney disease of unknown origin

In 2017, ANSTO's CEO signed a Memorandum of Understanding with Sri Lanka to work together to investigate the epidemiology of Chronic Kidney Disease of unknown origin (CKDu).

Pagination